Share Article
FOSTER CITY, Calif., Jul 20, 2010 (BUSINESS WIRE) --
Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share. Non-GAAP net income for the second quarter of 2010, which excludes after-tax acquisition-related expenses, restructuring expenses and stock-based compensation expenses, was $760.7 million, or $0.85 per diluted share. Non-GAAP net income for the second quarter of 2009, which excludes after-tax acquisition-related expenses, restructuring expenses and stock-based compensation expenses, was $648.9 million, or $0.69 per diluted share.
Product Sales
Product sales increased 15 percent to $1.81 billion for the second quarter of 2010, compared to $1.57 billion in the second quarter of 2009. This increase in sales was driven primarily by Gilead's antiviral franchise, due to the strong growth in sales of Atripla(R) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
Antiviral Franchise
Antiviral product sales increased 13 percent to $1.59 billion in the second quarter of 2010, up from $1.41 billion for the same quarter of 2009.
- Atripla
Sales of Atripla for the treatment of HIV infection increased 26 percent to $715.8 million for the second quarter of 2010, up from $569.1 million in the second quarter of 2009, driven primarily by sales volume growth in the United States and Europe.
- Truvada
Sales of Truvada(R) (emtricitabine/tenofovir disoproxil fumarate) for the treatment of HIV infection increased 6 percent to $641.7 million for the second quarter of 2010, up from $608.1 million in the second quarter of 2009, driven primarily by increased prices in the United States as well as sales volume growth in the United State and Europe.
- Viread
Sales of Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and chronic hepatitis B increased 11 percent to $176.2 million for the second quarter of 2010, up from $158.9 million in the second quarter of 2009, driven primarily by sales volume growth in the United States and Europe.
Letairis
Sales of Letairis(R) (ambrisentan) for the treatment of pulmonary arterial hypertension increased 37 percent to $60.3 million for the second quarter of 2010, up from $44.1 million for the second quarter of 2009, driven primarily by sales volume growth in the United States.
Ranexa
Sales of Ranexa(R) (ranolazine) for the treatment of chronic angina increased 68 percent to $60.5 million for the second quarter of 2010, up from $36.1 million for the second quarter of 2009, driven primarily by sales volume growth in the United States. Ranexa sales for the second quarter of 2009 began on April 15, 2009, the date Gilead acquired CV Therapeutics, Inc.
Other Products
Sales of AmBisome(R) (amphotericin B liposome for injection) for the treatment of severe fungal infections, Hepsera(R) (adefovir dipivoxil) for the treatment of chronic hepatitis B, Emtriva(R) (emtricitabine) for the treatment of HIV infection and other products were $151.6 million for the second quarter of 2010 compared to $152.0 million for the second quarter of 2009. Sales of Cayston(R) (aztreonam for inhalation solution) as a treatment for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa (P. aeruginosa), included in other products, were $10.5 million for the second quarter of 2010. Cayston was approved by the U.S. Food and Drug Administration (FDA) in February 2010.
Royalty, Contract and Other Revenues
Royalty, contract and other revenues resulting primarily from collaborations with corporate partners were $121.2 million in the second quarter of 2010, up from $78.8 million in the second quarter of 2009. This increase was driven primarily by higher Tamiflu(R) (oseltamivir phosphate) royalties from F. Hoffmann-La Roche Ltd of $83.8 million in the second quarter of 2010, compared to Tamiflu royalties of $51.9 million in the second quarter of 2009, resulting from increased sales related to influenza pandemic planning initiatives worldwide.
Research and Development
Research and development (R&D) expenses in the second quarter of 2010 were $231.1 million, compared to $241.6 million for the second quarter of 2009. Non-GAAP R&D expenses for the second quarter of 2010, which exclude restructuring and stock-based compensation expenses, were $207.4 million, relatively flat when compared to $206.1 million for the second quarter of 2009, which exclude restructuring and stock-based compensation expenses.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses in the second quarter of 2010 were $248.0 million, compared to $261.4 million for the second quarter of 2009. Non-GAAP SG&A expenses for the second quarter of 2010, which exclude restructuring and stock-based compensation expenses, were $223.5 million, compared to $213.2 million for the second quarter in 2009, which exclude acquisition-related, restructuring and stock-based compensation expenses. The increase in non-GAAP SG&A expenses was driven primarily by higher headcount and expenses to support Gilead's expanding commercial activities.
Net Foreign Currency Exchange Impact
The net foreign currency exchange impact on second quarter 2010 revenues and pre-tax earnings, which includes revenues and expenses generated from outside the United States, was an unfavorable $16.3 million and $19.5 million, respectively, compared to the second quarter of 2009, and an unfavorable $18.5 million and $16.5 million, respectively, compared to the first quarter of 2010.
Cash, Cash Equivalents and Marketable Securities
As of June 30, 2010, Gilead had cash, cash equivalents and marketable securities of $4.22 billion compared to $3.90 billion as of December 31, 2009. Gilead generated $1.37 billion of operating cash flow for the first six months of 2010 including $699.0 million in the second quarter of 2010.
Corporate Highlights
In May, Gilead announced that it had completed the $1.0 billion stock repurchase program that was authorized by its Board of Directors in January 2010, and that its Board of Directors had authorized an additional repurchase of up to $5.0 billion of its common stock through May 2013. During the second quarter of 2010, Gilead repurchased and retired 44.3 million shares of its common stock for $1.69 billion at an average purchase price of $38.14 per share.
In June:
- Gilead and the AIDS Drug Assistance Program (ADAP) Crisis Task Force announced a series of initiatives to help state ADAPs continue to provide antiretroviral medicines to people living with HIV in the United States.
- Gilead announced that John G. McHutchison, MD, will join the company as Senior Vice President, Liver Disease Therapeutics. In this position, Dr. McHutchison will report to Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer and will have responsibility for Gilead's R&D efforts supporting the company's programs in liver disease, including hepatitis C.
- Gilead announced an agreement to acquire CGI Pharmaceuticals, Inc. (CGI) for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand. This transaction closed on July 8, at which time CGI became a wholly-owned subsidiary of Gilead.
Product and Pipeline Update
Antiviral Franchise
In April:
- Gilead announced that it had dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350) and Truvada. The Phase III clinical program for the Quad includes two studies (Studies 102 and 103) that will evaluate the Quad regimen versus a standard of care among HIV-1 infected antiretroviral treatment- naïve adults. By the end of July, Gilead anticipates completing patient enrollment in Study 102, the first of these two studies to begin screening patients.
- Gilead provided an update on the development of the fixed-dose combination of Truvada and Tibotec's investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride, 25 mg). Johnson & Johnson, which owns Tibotec, announced that the two pivotal Phase III studies evaluating TMC278 as a treatment for HIV in treatment-naïve patients met the primary efficacy objective of non-inferiority as compared to efavirenz based on the proportion of patients achieving HIV RNA levels of less than 50 copies/mL at 48 weeks. These data will be presented in a late-breaker oral session on July 22, 2010 at the International AIDS Conference taking place in Vienna, Austria. Johnson & Johnson also announced in April that the submission of TMC278 for regulatory review is on track for the third quarter of this year.
- Gilead announced that it had obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada and TMC278. Gilead anticipates submitting a New Drug Application (NDA) to the FDA for the fixed-dose combination following validation of the TMC278 NDA.
Respiratory Franchise
In June, Gilead announced that its head-to-head Phase III clinical trial of Cayston versus tobramycin inhalation solution in cystic fibrosis patients with P. aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment. These data were presented during a late-breaker oral session at the 33rd European Cystic Fibrosis Conference in Valencia, Spain on June 18, 2010.
Conference Call
At 5:00 p.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss its second quarter 2010 results as well as provide a general business update. To access the webcast live via the internet, please connect to the company's website at www.gilead.com 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-866-804-6924 (U.S.) or 1-857-350-1670 (international) and dial the participant passcode 56303352 to access the call. Please note that Gilead's earnings results slides are also posted to the company's website at www.gilead.com.
A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through July 23, 2010. To access the phone replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 73162116.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with GAAP and also on a non-GAAP basis for the three and six months ended June 30, 2010 and 2009. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under U.S. GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on page 7.
Forward-looking Statements
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead's ability to sustain growth in revenues for its antiviral, cardiovascular and respiratory franchises; unpredictable variability of Tamiflu royalties and the strong relationship between this royalty revenue and global pandemic planning and supply; Gilead's ability to submit NDAs for new product candidates, including the fixed-dose combination of Truvada and TMC278, in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350) and Truvada and the fixed-dose combination of Truvada and TMC278, both for the treatment of HIV infection; Gilead's ability to successfully commercialize its products, including Cayston as a treatment for the improvement of respiratory symptoms in cystic fibrosis patients with P. aeruginosa; Gilead's ability to successfully develop its respiratory and cardiovascular franchises; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including the Quad and the fixed-dose combination of Truvada and TMC278; initiating and completing clinical trials may take longer or cost more than expected, including in the clinical studies evaluating the Quad for the treatment of HIV infection; fluctuations in the foreign exchange rate of the U.S. dollar that may reduce or eliminate the favorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; Gilead's ability to consummate the $5.0 billion share repurchase program due to changes in its stock price, corporate or other market conditions; risks and uncertainties related to Gilead's ability to successfully advance CGI's pipeline programs; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market-specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, other publicly filed disclosure documents filed with the Securities and Exchange Commission and subsequent press releases. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Truvada, Viread, Hepsera, Emtriva, AmBisome, Letairis, Cayston and Ranexa areregistered trademarks of Gilead Sciences, Inc.
Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Tamiflu is a registered trademark of F. Hoffmann-La Roche Ltd.
For more information on Gilead Sciences, Inc.,please visit www.gilead.com orcall the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
| GILEAD SCIENCES, INC. | ||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME | ||||||||||||||||||
| (unaudited) | ||||||||||||||||||
| (in thousands, except per share amounts) | ||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||
| June 30, | June 30, | |||||||||||||||||
| 2010 | 2009 | 2010 | 2009 | |||||||||||||||
| Revenues: | ||||||||||||||||||
| Product sales | $ | 1,806,061 | $ | 1,568,378 | $ | 3,594,124 | $ | 3,015,958 | ||||||||||
| Royalty, contract and other revenues | 121,163 | 78,777 | 418,953 | 161,657 | ||||||||||||||
| Total revenues | 1,927,224 | 1,647,155 | 4,013,077 | 3,177,615 | ||||||||||||||
| Costs and expenses: | ||||||||||||||||||
| Cost of goods sold | 455,525 | 383,045 | 895,955 | 712,459 | ||||||||||||||
| Research and development | 231,066 | 241,638 | 449,730 | 430,417 | ||||||||||||||
| Selling, general and administrative | 248,006 | 261,411 | 513,624 | 465,362 | ||||||||||||||
| Total costs and expenses | 934,597 | 886,094 | 1,859,309 | 1,608,238 | ||||||||||||||
| Income from operations | 992,627 | 761,061 | 2,153,768 | 1,569,377 | ||||||||||||||
| Interest and other income, net | 18,285 | 12,923 | 33,930 | 17,081 | ||||||||||||||
| Interest expense | (17,764 | ) | (18,484 | ) | (34,719 | ) | (35,155 | ) | ||||||||||
| Income before provision for income taxes | 993,148 | 755,500 | 2,152,979 | 1,551,303 | ||||||||||||||
| Provision for income taxes | 284,021 | 186,355 | 591,758 | 395,582 | ||||||||||||||
| Net income | 709,127 | 569,145 | 1,561,221 | 1,155,721 | ||||||||||||||
| Net loss attributable to noncontrolling interest | 2,934 | 2,253 | 5,741 | 4,789 | ||||||||||||||
| Net income attributable to Gilead | $ | 712,061 | $ | 571,398 | $ | 1,566,962 | $ | 1,160,510 | ||||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 0.81 | $ | 0.63 | $ | 1.76 | $ | 1.28 | ||||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 0.79 | $ | 0.61 | $ | 1.71 | $ | 1.24 | ||||||||||
| Shares used in per share calculation - basic | 881,802 | 905,611 | 891,649 | 907,684 | ||||||||||||||
| Shares used in per share calculation - diluted | 898,753 | 934,478 | 913,819 | 938,500 | ||||||||||||||
| GILEAD SCIENCES, INC. | |||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| (in thousands, except percentages and per share amounts) | |||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2010 | 2009 | 2010 | 2009 | ||||||||||||||
| Cost of goods sold reconciliation: | |||||||||||||||||
| GAAP cost of goods sold | $ | 455,525 | $ | 383,045 | $ | 895,955 | $ | 712,459 | |||||||||
| Acquisition-related amortization of inventory mark-up | (2,042 | ) | (3,711 | ) | (7,020 | ) | (3,711 | ) | |||||||||
| Acquisition-related amortization of purchased intangibles | (14,981 | ) | (12,066 | ) | (29,965 | ) | (12,066 | ) | |||||||||
| Stock-based compensation expenses | (2,967 | ) | (2,771 | ) | (5,820 | ) | (6,025 | ) | |||||||||
| Non-GAAP cost of goods sold | $ | 435,535 | $ | 364,497 | $ | 853,150 | $ | 690,657 | |||||||||
| Product gross margin reconciliation: | |||||||||||||||||
| GAAP product gross margin | 74.8 | % | 75.7 | % | 75.1 | % | 76.5 | % | |||||||||
| Acquisition-related amortization of inventory mark-up | 0.1 | % | 0.2 | % | 0.2 | % | 0.1 | % | |||||||||
| Acquisition-related amortization of purchased intangibles | 0.8 | % | 0.8 | % | 0.8 | % | 0.4 | % | |||||||||
| Stock-based compensation expenses | 0.2 | % | 0.2 | % | 0.2 | % | 0.2 | % | |||||||||
| Non-GAAP product gross margin (1) | 75.9 | % | 76.9 | % | 76.3 | % | 77.2 | % | |||||||||
| Research and development expenses reconciliation: | |||||||||||||||||
| GAAP research and development expenses | $ | 231,066 | $ | 241,638 | $ | 449,730 | $ | 430,417 | |||||||||
| Restructuring expenses | (2,130 | ) | (11,251 | ) | (4,230 | ) | (11,251 | ) | |||||||||
| Stock-based compensation expenses | (21,521 | ) | (24,321 | ) | (41,590 | ) | (41,276 | ) | |||||||||
| Non-GAAP research and development expenses | $ | 207,415 | $ | 206,066 | $ | 403,910 | $ | 377,890 | |||||||||
| Selling, general and administrative expenses reconciliation: | |||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 248,006 | $ | 261,411 | $ | 513,624 | $ | 465,362 | |||||||||
| Acquisition-related transaction costs | - | (8,165 | ) | - | (8,165 | ) | |||||||||||
| Restructuring expenses | (906 | ) | (12,855 | ) | (13,490 | ) | (12,855 | ) | |||||||||
| Stock-based compensation expenses | (23,559 | ) | (27,189 | ) | (47,478 | ) | (48,025 | ) | |||||||||
| Non-GAAP selling, general and administrative expenses | $ | 223,541 | $ | 213,202 | $ | 452,656 | $ | 396,317 | |||||||||
| Operating margin reconciliation: | |||||||||||||||||
| GAAP operating margin | 51.5 | % | 46.2 | % | 53.7 | % | 49.4 | % | |||||||||
| Acquisition-related transaction costs | - | 0.5 | % | - | 0.3 | % | |||||||||||
| Acquisition-related amortization of inventory mark-up | 0.1 | % | 0.2 | % | 0.2 | % | 0.1 | % | |||||||||
| Acquisition-related amortization of purchased intangibles | 0.8 | % | 0.7 | % | 0.7 | % | 0.4 | % | |||||||||
| Restructuring expenses | 0.2 | % | 1.5 | % | 0.4 | % | 0.8 | % | |||||||||
| Stock-based compensation expenses | 2.5 | % | 3.3 | % | 2.4 | % | 3.0 | % | |||||||||
| Non-GAAP operating margin (1) | 55.0 | % | 52.4 | % | 57.4 | % | 53.9 | % | |||||||||
| Net income attributable to Gilead reconciliation: | |||||||||||||||||
| GAAP net income attributable to Gilead | $ | 712,061 | $ | 571,398 | $ | 1,566,962 | $ | 1,160,510 | |||||||||
| Acquisition-related transaction costs | - | 8,165 | - | 8,165 | |||||||||||||
| Acquisition-related amortization of inventory mark-up | 1,433 | 2,659 | 5,090 | 2,659 | |||||||||||||
| Acquisition-related amortization of purchased intangibles | 10,721 | 8,909 | 21,729 | 8,909 | |||||||||||||
| Restructuring expenses | 2,061 | 17,792 | 12,849 | 17,792 | |||||||||||||
| Stock-based compensation expenses | 34,395 | 39,961 | 68,808 | 70,249 | |||||||||||||
| Non-GAAP net income attributable to Gilead | $ | 760,671 | $ | 648,884 | $ | 1,675,438 | $ | 1,268,284 | |||||||||
| Diluted earnings per share reconciliation: | |||||||||||||||||
| GAAP diluted earnings per share | $ | 0.79 | $ | 0.61 | $ | 1.71 | $ | 1.24 | |||||||||
| Acquisition-related transaction costs | - | 0.01 | 0.00 | 0.01 | |||||||||||||
| Acquisition-related amortization of inventory mark-up | 0.00 | 0.00 | 0.01 | 0.00 | |||||||||||||
| Acquisition-related amortization of purchased intangibles | 0.01 | 0.01 | 0.02 | 0.01 | |||||||||||||
| Restructuring expenses | 0.00 | 0.02 | 0.01 | 0.02 | |||||||||||||
| Stock-based compensation expenses | 0.04 | 0.04 | 0.08 | 0.07 | |||||||||||||
| Non-GAAP diluted earnings per share (1) | $ | 0.85 | $ | 0.69 | $ | 1.84 | $ | 1.35 | |||||||||
| Shares used in per share calculation (diluted) reconciliation: | |||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 898,753 | 934,478 | 913,819 | 938,500 | |||||||||||||
| Share impact of current stock-based compensation guidance | (1,555 | ) | 28 | (1,262 | ) | 397 | |||||||||||
| Non-GAAP shares used in per share calculation (diluted) | 897,198 | 934,506 | 912,557 | 938,897 | |||||||||||||
| Non-GAAP adjustment summary: | |||||||||||||||||
| Cost of goods sold adjustments | $ | 19,990 | $ | 18,548 | $ | 42,805 | $ | 21,802 | |||||||||
| Research and development expenses adjustments | 23,651 | 35,572 | 45,820 | 52,527 | |||||||||||||
| Selling, general and administrative expenses adjustments | 24,465 | 48,209 | 60,968 | 69,045 | |||||||||||||
| Total non-GAAP adjustments before tax | 68,106 | 102,329 | 149,593 | 143,374 | |||||||||||||
Income tax effect | (19,496 | ) | (24,843 | ) | (41,117 | ) | (35,600 | ) | |||||||||
| Total non-GAAP adjustments after tax | $ | 48,610 | $ | 77,486 | $ | 108,476 | $ | 107,774 | |||||||||
| Note: | |||||||||||||||||
| (1) Amounts may not sum due to rounding | |||||||||||||||||
| GILEAD SCIENCES, INC. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (in thousands) | |||||||
| June 30, | December 31, | ||||||
| 2010 | 2009 | ||||||
| (unaudited) | (Note 1) | ||||||
| Cash, cash equivalents and marketable securities | $ | 4,217,535 | $ | 3,904,846 | |||
| Accounts receivable, net | 1,482,900 | 1,389,534 | |||||
| Inventories | 1,356,606 | 1,051,771 | |||||
| Property, plant and equipment, net | 695,043 | 699,970 | |||||
| Intangible assets | 1,494,813 | 1,524,777 | |||||
| Other assets | 1,249,811 | 1,127,661 | |||||
| Total assets | $ | 10,496,708 | $ | 9,698,559 | |||
| Current liabilities | $ | 3,105,723 | $ | 1,871,631 | |||
| Long-term liabilities | 690,985 | 1,321,770 | |||||
| Stockholders' equity | 6,700,000 | 6,505,158 | |||||
| Total liabilities and stockholders' equity | $ | 10,496,708 | $ | 9,698,559 | |||
| Notes: | |||||||
| (1) | Derived from audited consolidated financial statements at that date. | ||||||
| GILEAD SCIENCES, INC. | |||||||||||||
| PRODUCT SALES SUMMARY | |||||||||||||
| (unaudited) | |||||||||||||
| (in thousands) | |||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||
| June 30, | June 30, | ||||||||||||
| 2010 | 2009 | 2010 | 2009 | ||||||||||
| Antiviral products: | |||||||||||||
| Atripla - U.S. | $ | 466,819 | 398,044 | $ | 922,720 | $ | 772,176 | ||||||
| Atripla - Europe | 221,149 | 154,835 | 438,697 | 279,614 | |||||||||
| Atripla - Other International | 27,836 | 16,263 | 47,259 | 27,235 | |||||||||
| 715,804 | 569,142 | 1,408,676 | 1,079,025 | ||||||||||
| Truvada - U.S. | 317,522 | $ | 285,688 | 644,339 | 566,685 | ||||||||
| Truvada - Europe | 278,373 | 287,777 | 575,901 | 566,217 | |||||||||
| Truvada - Other International | 45,787 | 34,614 | 79,241 | 65,530 | |||||||||
| 641,682 | 608,079 | 1,299,481 | 1,198,432 | ||||||||||
| Viread - U.S. | 78,787 | 67,858 | 156,794 | 137,447 | |||||||||
| Viread - Europe | 71,004 | 66,009 | 144,147 | 131,340 | |||||||||
| Viread - Other International | 26,381 | 25,058 | 55,917 | 50,743 | |||||||||
| 176,172 | 158,925 | 356,858 | 319,530 | ||||||||||
| Hepsera - U.S. | 19,470 | 22,771 | 41,035 | 48,423 | |||||||||
| Hepsera - Europe | 28,551 | 40,797 | 61,926 | 79,714 | |||||||||
| Hepsera - Other International | 3,313 | 3,506 | 6,497 | 11,651 | |||||||||
| 51,334 | 67,074 | 109,458 | 139,788 | ||||||||||
| Emtriva - U.S. | 4,135 | 3,716 | 8,379 | 7,346 | |||||||||
| Emtriva - Europe | 1,684 | 2,210 | 3,559 | 4,506 | |||||||||
| Emtriva - Other International | 926 | 1,170 | 1,963 | 2,420 | |||||||||
| 6,745 | 7,096 | 13,901 | 14,272 | ||||||||||
| - | |||||||||||||
| Total Antiviral products - U.S. | 886,733 | 778,077 | 1,773,267 | 1,532,077 | |||||||||
| Total Antiviral products - Europe | 600,761 | 551,628 | 1,224,230 | 1,061,391 | |||||||||
| Total Antiviral products - Other International | 104,243 | 80,611 | 190,877 | 157,579 | |||||||||
| 1,591,737 | 1,410,316 | 3,188,374 | 2,751,047 | ||||||||||
| - | |||||||||||||
| AmBisome | 78,174 | 73,310 | 155,223 | 137,581 | |||||||||
| Letairis | 60,348 | 44,128 | 115,847 | 83,708 | |||||||||
| Ranexa | 60,460 | 36,065 | 111,703 | 36,065 | |||||||||
| Other products | 15,342 | 4,559 | 22,977 | 7,557 | |||||||||
| 214,324 | 158,062 | 405,750 | 264,911 | ||||||||||
| - | |||||||||||||
| Total product sales | $ | 1,806,061 | $ | 1,568,378 | $ | 3,594,124 | $ | 3,015,958 | |||||
SOURCE: Gilead Sciences, Inc.
Gilead Sciences, Inc.InvestorsRobin Washington, 650-522-5688Susan Hubbard, 650-522-5715MediaAmy Flood, 650-522-5643
Investors
Jacquie Ross
investors_relations@gilead.com
Media Contact
Meaghan Smith
public_affairs@gilead.com
Other News
Some of the content on this page is not intended for users outside the U.S.